The experiments we present in this manuscript suggest that Lck inhibitors may be biologically useful because treatment of CLL cells with Lck-i promotes expression of S1PR1 to facilitate migration to S1P. The gene discussed is MBTPS1; the disease is B-cell chronic lymphocytic leukemia.